Oral GLP-1 Orforglipron Performs Well in Phase 3 T2D Trials

Published Date: 11 Jun 2026

Phase 3 trials of the oral nonpeptide show glycemic and weight benefit when added to glargine and compared with dapagliflozin and oral semaglutide, but with somewhat lower tolerability.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Chromatin organization linked to p53 tumor suppression mechanism

2.

Despite Medicare Coverage, Cancer Genomic Testing Still Low

3.

High Rate of Surgical Success in Complex NSCLC With Neoadjuvant Chemoimmunotherapy

4.

New protein target discovered for childhood medulloblastomas

5.

CAR T-Cell Therapy for Kidney Cancer Builds on Efficacy Record


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot